Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
INVENTVACC BIOLOGICALS INC. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for INVENTVACC BIOLOGICALS INC.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
InventisBio, Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for InventisBio, Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
8 min read
Intra-ImmuSG Pte Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Intra-ImmuSG Pte Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
Institut Jean Paoli & Irene Calmettes Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Institut Jean Paoli & Irene Calmettes: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach
Read →
Latest Hotspot
9 min read
Insmed, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Insmed, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
8 min read
Inozyme Pharma, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Inozyme Pharma, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
Innovent Biologics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Innovent Biologics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
Innovent Biologics (Suzhou) Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Innovent Biologics (Suzhou) Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r
Read →
Latest Hotspot
9 min read
Inimmune Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Inimmune Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
Inibio, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Inibio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Latest Hotspot
9 min read
Inhibikase Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Inhibikase Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational
Read →
Latest Hotspot
9 min read
Incyte Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Incyte Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
<
1
<<
1057
1058
1059
1060
1061
>>
2926
>